Agenus (AGEN)
(Delayed Data from NSDQ)
$5.09 USD
-0.19 (-3.60%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $5.07 -0.02 (-0.39%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth B Momentum C VGM
Brokerage Reports
0 items in cart
Agenus Inc. [AGEN]
Reports for Purchase
Showing records 181 - 200 ( 260 total )
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Transferring Coverage and maintaining rating of Market Outperform with $7 price target.
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
What Was Supposed to Be a Quiet Week Turns Into a Busy Week
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Prophage GBM Data Published in Peer Reviewed Journal
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
2Q12 Results; Moving Quickly Toward Catalysts; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
GSK Initiates a Phase III Trial of QS-21 Based Vaccine for Shingles
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
GSK Initiates a Phase III Trial of QS-21 Based Vaccine for Shingles
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
GSK Launches Additional Phase III Study of QS-21-containing Vaccine
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
We are placing Agenus under review due to the departure of the covering analyst
Provider: RODMAN & RENSHAW, CO.
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Added Color from KOL on Prophage and Next Steps
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
1Q12 UPDATE - G-200 RANDOMIZED STUDIES WITH NIH - PHASE 3 DATA IN 2013
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
1Q12 UPDATE - G-200 RANDOMIZED STUDIES WITH NIH - PHASE 3 DATA IN 2013
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
1Q12 Results; All Programs Growing and On Track; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.